Although little progress has been made in regards to inhibiting Src and other SFKs in order to treat cancer due to the complexity of the signaling pathways involved in the control of many cellular functions and the development of resistance, increased efforts open new hopes for success, particularly using combinatorial therapeutic regimes (as reviewed in [5,154,155]). The gene discussed is SRC; the disease is cancer.